3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Ovarian Neoplasms
4
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Carcinoma, Renal Cell
2
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Neoplasm Metastasis
1
Microsatellite Instability
1
Lymphoma, Large B-Cell, Diffuse
1
Kidney Neoplasms
1
Kidney Diseases
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Merkel Cell
1
Interventions
Rituximab
66
Cyclophosphamide
46
Vincristine
40
Doxorubicin
40
Prednisone
35
Etoposide
19
Radiotherapy
14
Gemcitabine
13
Peripheral Blood Stem Cell Transplantation
12
Filgrastim
12
Cytarabine
12
Lenalidomide
11
Carmustine
10
VAP-cyclo protocol
9
Prednisolone
9
Oxaliplatin
9
Melphalan
9
Methotrexate
7
Ifosfamide
7
Mitoxantrone
6
Bleomycin
6
polatuzumab vedotin
5
R-CHOP protocol
4
Methylprednisolone
4
Injections
4
Granulocyte Colony-Stimulating Factor
4
Cyclosporine
4
Cisplatin
4
Carboplatin
4
pegfilgrastim
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Large B-Cell, Diffuse
×
avelumab
×
Clear all
NCT02951156
2020-12-17
Javelin DLBCL
Pfizer
Phase 3
Terminated
29 enrolled
24 charts